Allogeneic hematopoietic cell transplant pathway for JMML

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	None declared

ID	`REG-ALLOHCT-JMML`
Type	Regimen
Status	reviewed 2026-05-11
Diseases	None declared
Sources	`SRC-COG`

Notes

Minimal pathway entity to make JMML treatment routing executable. JMML is pediatric and transplant-centered; the exact conditioning regimen and any azacitidine/cytoreductive bridge are institution-specific and require pediatric transplant team review.

Used By

Indication

IND-JMML-1L-ALLOHCT - IND-JMML-1L-ALLOHCT